Article
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.
The Lancet. Oncology - 1 Jan 2026
van den Bent Martin J, Ghisai Santoesha A, Wick Wolfgang, Sanson Marc, Brandes Alba Ariela, Clement Paul M, Erridge Sara C, Vogelbaum Michael A, Nowak Anna K, Baurain Jean-François, Mason Warren P, Wheeler Helen, Tabouret Emeline, Gill Sanjeev, Griffin Matthew, Taal Walter, Rudà Roberta, Weller Michael, McBain Catherine, Reijneveld Jaap C, Enting Roelien H, Tran Sébastien, Lesimple Thierry, Kocher Martin, Gijtenbeek Anja, Lim Elizabeth, Herrlinger Ulrich, Hau Peter, Dhermain Frederic, Aldape Kenneth, Jenkins Robert B, Dubbink Hendrikus Jan, Kros Johan M, Wesseling Pieter, Hoogstrate Youri, Nuyens Sarah, Golfinopoulos Vassilis, Tesileanu C Mircea S, Gorlia Thierry, French Pim, Baumert Brigitta G
Abstract excerpt
BACKGROUND: The CATNON trial investigated the benefit of the addition of concurrent or adjuvant temozolomide to radiotherapy in individuals with anaplastic astrocytoma. We report the long-term follow-up of the study focusing on the individuals with isocitrate dehydrogenase (IDH) mutated (IDHmt) tumours. METHODS: This randomised, open-label, phase 3 study in 137 institutions across Australia, Europe, and North...
Topics
Join the communities discussing this publication.